Group Pleyer

Working group:
Myeloid Neoplasias

Group leader: PD Dr. DI Lisa Pleyer

Since 2009 we have been investigating myeloid neoplasias, with the main focus on myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML), as well as various overlap syndromes (Figure 1). In 2010, we published an educational textbook on chronic myeloid neoplasias and overlap syndromes (Figure 2).

We founded a national patient registry of patients with MDS, AML and CMML treated with hypomethylating agents (HMAs). This registry is by now one of the largest and most well documented registries in this indication world-wide, and many fruitful national and international colaborations have resulted. This registry encompasses anonymous documentation of toxicities, response, and survival of patients with above mentioned diseases that are treated with HMAs.

In MDS, AML and CMML, so-called epigenetic changes are present and involved in disease pathogenesis. An example of how powerful epigenetics can be, is for example the transformation of a caterpillar to a butterfly. Both animals share the same genome (DNA sequence), but harbor different epigenetic changes, that result in the switching on or off of different genes, that can be ‘read’ and ‘translated’ into proteins. Epigenetic changes include DNA hypo- and hypermethylation, as well as methylation and acetylation changes of histone molecules, which may be described as spools, around which the DNA is wrapped. Depending on how the DNA is methylated, and how the histones are acetylated, the DNA can either be wrapped more tightly around the histones, resulting in a closed chromatin structure. In this closed state, tumor suppressor genes cannot be ‘read’ or ‘transcribed’, which may result in tumor initiation, propagation and/or progression. Treatment with HMAs results in a (partial) reversal of this hypermethylated state, and consequently leads to the unwrapping of DNA from the histones, and in a looser, more open chromatin structure. This is a state, where transcription factors can bind to the DNA and result in the reactivation and re-expression of tumor suppressor genes, among other effects. Thus HMAs can help eliminate myeloid cancer cells.

Our aim is to identify biomarkers, which may help predict which patients are the most likely to profit from treatment with HMAs. Other research interests of our group include the analyses of mutations and clonal evolution during the course of the diseases, as well as interactions of the malignant cells with various cells of the immune system, and, more specifically, the numerical changes of these cells during patient treatment with HMAs (Figure 3).

Effects of leukemic cells on immune cells

Leukemic cells modulate the microenvironment in general, and the immune system in particular, to create an environment, that allows the tumor to escape the control of the immune system (so-called ‘immune evasion’), and is permissive to further tumor cell growth. New targeted therapies, directed e.g. against certain checkpoint molecules on immune cells, can help reverse the tumor-induced micro-environmental changes. Ideally, these new drugs can change an immunosuppressive microenvironment to a tumor suppressive microenvironment, and thus ultimately help the bodies own immune system to eliminate cancer cells, or at least to control their growth.

Another part of our group is currently involved in establishing new techniques on how best to filter circulating cancer cells out of the peripheral blood, which will enable us to analyze tumor cells more closely in the future (Figure 4).

2018

Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial.

Westphal, T, Rinnerthaler, G, Gampenrieder, SP, Niebauer, J, Thaler, J, Pfob, M, Fuchs, D, Riedmann, M, Mayr, B, Reich, B, Melchardt, T, Mlineritsch, B, Pleyer, L, Greil, R.
Cancer Med. 2018.

View this publication in the PUBMED database

Time to repeal and replace response criteria for acute myeloid leukemia?

Bloomfield, CD, Estey, E, Pleyer, L, Schuh, AC, Stein, EM, Tallman, MS, Wei, A.
Blood Rev. 2018, 32(5):416-425.

View this publication in the PUBMED database

Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Egle, A, Steurer, M, Melchardt, T, Weiss, L, Gassner, FJ, Zaborsky, N, Geisberger, R, Catakovic, K, Hartmann, TN, Pleyer, L, Voskova, D, Thaler, J, Lang, A, Girschikofsky, M, Petzer, A, Greil, R.
Ann Hematol. 2018.

View this publication in the PUBMED database

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia.

Ball, B, Komrokji, RS, Ades, L, Sekeres, MA, DeZern, AE, Pleyer, L, Vey, N, Almeida, A, Germing, U, Cluzeau, T, Platzbecker, U, Gore, SD, Fenaux, P, Prebet, T.
BLOOD ADV. 2018, 2(16): 2063-2071.

View this publication in the PUBMED database

Remission maintenance treatment options in chronic lymphocytic leukemia.

Egle, A, Pleyer, L, Melchardt, T, Hartmann, TN, Greil, R.
Cancer Treat Rev. 2018, 70:5-66.

View this publication in the PUBMED database

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Egle, A, Steurer, M, Melchardt, T, Weiss, L, Gassner, FJ, Zaborsky, N, Geisberger, R, Catakovic, K, Hartman, TN, Pleyer, L, Voskova, D, Thaler, J, Lang, A, Girschikofsky, M, Petzer, A, Greil, R.
Ann Hematol. 2018.

View this publication in the PUBMED database

Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations.

Greil, R, Pleyer, L, Jansko, B, Feierabend, C, Rettenbacher, L, Stiefel, O, Rass, C, Morre, P, Neureiter, D, Greil-Ressler, S.
Oncotarget. 2018, 9(29):20928-20940.

View this publication in the PUBMED database

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).

Falantes, J, Pleyer, L, Thépot, S, Almeida, AM, Maurillo, L, Martínez-Robles, V, Stauder, R, Itzykson, R, Pinto, R, Venditti, A, Bargay, J, Burgstaller, S, Martínez, MP, Seegers, V, Cortesão, E, Foncillas, MÁ, Gardin, C, Montesinos, P, Musto, P, Fenaux, P, Greil, R, Sanz, MA, Ramos, F,
Leuk Lymphoma. 2018, 59(5):1113-1120.

View this publication in the PUBMED database

Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.

Melchardt, T, Magnes, T, Hufnagl, C, Thorner, AR, Ducar, M, Neureiter, D, Tränkenschuh, W, Klieser, E, Gaggl, A, Rösch, S, Rasp, G, Hartmann, TN, Pleyer, L, Rinnerthaler, G, Weiss, L, Greil, R, Egle, A.
Eur J Cancer. 2018, 93:69-78.

View this publication in the PUBMED database

Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.

Huemer, F, Weiss, L, Faber, V, Neureiter, D, Egle, A, Geissler, K, Voskova, D, Zebisch, A, Burgstaller, S, Pichler, A, Stauder, R, Sperr, W, Lang, A, Pfeilstöcker, M, Machherndl-Spandl, S, Stampfl, M, Greil, R, Pleyer, L.
Wien Klin Wochenschr. 2018.

View this publication in the PUBMED database

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC – an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).

Huemer, F, Thaler, J, Piringer, G, Hackl, H, Pleyer, L, Hufnagl, C, Weiss, L, Greil, R.
BMC Cancer. 2018, 18(1): 11.

View this publication in the PUBMED database

Distribution of Curcumin and THC in Peripheral Blood Mononuclear Cells Isolated from Healthy Individuals and Patients with Chronic Lymphocytic Leukemia.

Bolger, GT, Licollari, A, Tan, A, Greil, R, Pleyer, L, Vcelar, B, Majeed, M, Sordillo, P.
Anticancer Res. 2018, 38(1): 12-130.

View this publication in the PUBMED database

2017

Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine – A retrospective single center experience.

Leisch, M, Weiss, L, Lindlbauer, N, Jungbauer, C, Egle, A, Rohde, E, Greil, R, Grabmer, C, Pleyer, L.
Leuk Res. 2017, 59:12-19.

View this publication in the PUBMED database

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.

Almeida, AM, Prebet, T, Itzykson, R, Ramos, F, Al-Ali, H, Shammo, J, Pinto, R, Maurillo, L, Wetzel, J, Musto, P, Van De Loosdrecht, AA, Costa, MJ, Esteves, S, Burgstaller, S, Stauder, R, Autzinger, EM, Lang, A, Krippl, P, Geissler, D, Falantes, JF, Pedro, C, Bargay, J, Deben, G, Garrido, A, Bonanad, S, Diez-Campelo, M, Thepot, S, Ades, L, Sperr, WR, Valent, P, Fenaux, P, Sekeres, MA, Greil, R, Pleyer, L.
INT J MOL SCI. 2017, 18(4): 837.

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.

Pleyer, L, Dohner, H, Dombret, H, Seymour, JF, Schuh, AC, Beach, CL, Swern, AS, Burgstaller, S, Stauder, R, Girschikofsky, M, Sill, H, Schlick, K, Thaler, J, Halter, B, Spandl, SM, Zebisch, A, Pichler, A, Pfeilstocker, M, Autzinger, EM, Lang, A, Geissler, K, Voskova, D, Sperr, WR, Hojas, S, Rogulj, IM, Andel, J, Greil, R.
INT J MOL SCI. 2017, 18(2): 415.

The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.

Wolff, F, Leisch, M, Greil, R, Risch, A, Pleyer, L.
Cell Commun Signal. 2017, 15(1):13.

View this publication in the PUBMED database

Reactivation of dormant anti-tumor immunity – a clinical perspective of therapeutic immune checkpoint modulation.

Greil, R, Hutterer, E, Hartmann, TN, Pleyer, L.
Cell Commun Signal. 2017, 15(1): 5.

View this publication in the PUBMED database

2016

Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.

Greil, R, Obrtlíková, P, Smolej, L, Kozák, T, Steurer, M, Andel, J, Burgstaller, S, Mikušková, E, Gercheva, L, Nösslinger, T, Papajík, T, Ladická, M, Girschikofsky, M, Hrubiško, M, Jäger, U, Fridrik, M, Pecherstorfer, M, Králiková, E, Burcoveanu, C, Spasov, E, Petzer, A, Mihaylov, G, Raynov, J, Oexle, H, Zabernigg, A, Flochová, E, Palášthy, S, Stehlíková, O, Doubek, M, Altenhofer, P, Pleyer, L, Melchardt, T, Klingler, A, Mayer, J, Egle, A.
Lancet Haematol. 2016, 3(7):e317-e329.

View this publication in the PUBMED database

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.

Pleyer, L, Burgstaller, S, Stauder, R, Girschikofsky, M, Sill, H, Schlick, K, Thaler, J, Halter, B, Machherndl-Spandl, S, Zebisch, A, Pichler, A, Pfeilstöcker, M, Autzinger, EM, Lang, A, Geissler, K, Voskova, D, Geissler, D, Sperr, WR, Hojas, S, Rogulj, IM, Andel, J, Greil, R.
J HEMATOL ONCOL. 2016, 9: 39.

View this publication in the PUBMED database

Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis Masters of Survival and Clonality?.

Pleyer, L, Valent, P, Greil, R.
INT J MOL SCI. 2016, 17(7): 1009.

View this publication in the PUBMED database

2015

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.

Ramos, F, Thépot, S, Pleyer, L, Maurillo, L, Itzykson, R, Bargay, J, Stauder, R, Venditti, A, Seegers, V, Martínez-Robles, V, Burgstaller, S, Récher, C, Debén, G, Gaidano, G, Gardin, C, Musto, P, Greil, R, Sánchez-Guijo, F, Fenaux, P.
Leuk Res. 2015, 39(3):29-306.

View this publication in the PUBMED database

10th anniversary of the Austrian MDS Platform: aims and ongoing projects.

Burgstaller, S, Bettelheim, P, Krieger, O, Machherndl-Spandl, S, Nösslinger, T, Pleyer, L, Sill, H, Sperr, WR, Stauder, R, Valent, P, Pfeilstöcker, M.
Wien Klin Wochenschr. 2015, 127(1-2): 12-15.

View this publication in the PUBMED database

Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics.

Melchardt, T, Weiss, L, Hufnagl, C, Neureiter, D, Kemmerling, R, Morre, P, Boekstegers, A, Hopfinger, G, Auberger, J, Steinkirchner, S, Pleyer, L, Greil, R, Egle, A.
Leuk Lymphoma. 2015, 56(2):353-360.

View this publication in the PUBMED database

“Digging deep into “”dirty”” drugs – modulation of the methylation machinery.”

Pleyer, L, Greil, R.
Drug Metab Rev. 2015, 47(2):252-279.

View this publication in the PUBMED database

Is It Time to Redefine Response in Elderly Patients with WHO-Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy?

Pleyer, L, Burgstaller, S, Stauder, R, Girschikofsky, M, Sill, H, Schlick, K, Thaler, J, Halter, B, Machherndl-Spandl, S, Zebisch, A, Pichler, A, Pfeilstocker, M, Autzinger, EM, Lang, A, Geissler, K, Voskova, D, Geissler, D, Sperr, WR, Hojas, S, Rogulj, IM, Andel, J, Greil, R.
BLOOD. 2015, 126(23).

View this publication in the PUBMED database

Azacitidine in Acute Myeloid Leukemia with > 30% Bone Marrow Blasts and < 15 G/L White Blood Cell Count: Results from the Austrian Azacitidine Registry of the AGMT Study Group Versus Randomized Controlled Phase III Clinical Trial Data

Pleyer, L, Burgstaller, S, Stauder, R, Girschikofsky, M, Sill, H, Schlick, K, Thaler, J, Halter, B, Machherndl-Spandl, S, Zebisch, A, Pichler, A, Pfeilstocker, M, Autzinger, EM, Lang, A, Geissler, K, Voskova, D, Geissler, D, Sperr, WR, Hojas, S, Rogulj, IM, Andel, J, Greil, R.
BLOOD. 2015, 126(23).

View this publication in the PUBMED database

Azacitidine in Older Patients with Acute Myeloid Leukemia (AML). Results from the Expanded International E-Alma Series (E-ALMA plus ) According to the MRC Risk Index Score

Falantes, J, Thepot, S, Pleyer, L, Maurillo, L, Martinez-Robles, V, Itzykson, R, Bargay, J, Stauder, R, Venditti, A, Martinez, MP, Seegers, V, Foncillas, MA, Burgstaller, S, Gardin, C, Montesinos, P, Musto, P, Greil, R, Sanz, M, Fenaux, P, Ramos, F.
BLOOD. 2015, 126(23).

View this publication in the PUBMED database

CLINICAL OUTCOMES OF ACUTE ERYTHROLEUKEMIA TREATED WITH AZACITIDINE: A RETROSPECTIVE MULTICENTER STUDY

Almeida, A, Prebet, T, Itzykson, R, Ramos, F, Al Ali, HK, Shammo, J, Pinto, R, Maurillo, L, WetzeI, J, Musto, P, van de Loosdrecht, A, Costa, MJ, Burgstaller, S, Stauder, R, Auzinger, G, Lang, A, Krippl, P, Geissler, D, Falantes, JF, Pedro, C, Bargay, J, Deben, G, Garrido, A, Bonanad, S, Diez-Campelo, M, Fenaux, P, Thepot, S, Ades, L, Sekeres, M, Greil, R, Pleyer, L.
HAEMATOLOGICA. 2015, 100: 384-384.

View this publication in the PUBMED database

MRD dynamics after chemoimmunotherapy induction treatment of CLL independently predict outcome: first analysis of a secondary endpoint from the international randomized AGMT-CLL8/a Mabtenance trial

Egle, A, Doubek, M, Stehlikova, O, Pleyer, L, Altenhofer, P, Melchardt, T, Smolej, L, Mihaylov, GG, Mikuskova, E, Mayer, J, Greil, R.
LEUKEMIA LYMPHOMA. 2015, 56: 123-124.

View this publication in the PUBMED database

2014

Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival.

Pleyer, L, Germing, U, Sperr, WR, Linkesch, W, Burgstaller, S, Stauder, R, Girschikofsky, M, Schreder, M, Pfeilstocker, M, Lang, A, Sliwa, T, Geissler, D, Schlick, K, Placher-Sorko, G, Theiler, G, Thaler, J, Mitrovic, M, Neureiter, D, Valent, P, Greil, R.
Leuk Res. 2014, 38(4): 475-483.

View this publication in the PUBMED database

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group.

Pleyer, L, Burgstaller, S, Girschikofsky, M, Linkesch, W, Stauder, R, Pfeilstocker, M, Schreder, M, Tinchon, C, Sliwa, T, Lang, A, Sperr, WR, Krippl, P, Geissler, D, Voskova, D, Schlick, K, Thaler, J, Machherndl-Spandl, S, Theiler, G, Eckmüllner, O, Greil, R.
ANN HEMATOL. 2014, 93(11): 1825-1838.

View this publication in the PUBMED database

Azacitidine in Patients with Relapsed/Refractory Acute Myeloid Leukemia : Retrospective Analysis of the Austrian Azacitidine Registry

Pleyer, L, Burgstaller, S, Stauder, R, Girschikofsky, M, Linkesch, W, Pfeilstocker, M, Autzinger, EM, Tinchon, C, Sliwa, T, Lang, A, Sperr, WR, Geissler, D, Krippl, P, Voskova, D, Rossmann, DH, Schlick, K, Thaler, J, Halter, B, Machherndl-Spandl, S, Theiler, G, Valent, P, Eckmullner, O, Greil, R
BLOOD. 2014, 124(21):

View this publication in the PUBMED database

Azacitidine in Patients with Acute Myeloid Leukemia: Assessing the Potential Negative Impact of Elevated Baseline White Blood Cell Count on Outcome

Pleyer, L, Burgstaller, S, Stauder, R, Girschikofsky, M, Linkesch, W, Pfeilstocker, M, Autzinger, EM, Tinchon, C, Sliwa, T, Lang, A, Sperr, WR, Geissler, D, Krippl, P, Voskova, D, Rossmann, DH, Schlick, K, Thaler, J, Halter, B, Machherndl-Spandl, S, Theiler, G, Valent, P, Eckmullner, O, Greil, R
BLOOD. 2014, 124(21):

View this publication in the PUBMED database

Azacitidine in Acute Myeloid Leukemia: Comparison of Patients with AML-MRF Vs AML-NOS Enrolled in the Austrian Azacitidine Registry

Pleyer, L, Burgstaller, S, Stauder, R, Girschikofsky, M, Linkesch, W, Pfeilstocker, M, Autzinger, EM, Tinchon, C, Sliwa, T, Lang, A, Sperr, WR, Geissler, D, Krippl, P, Voskova, D, Rossmann, DH, Schlick, K, Thaler, J, Halter, B, Machherndl-Spandl, S, Theiler, G, Valent, P, Eckmullner, O, Greil, R
BLOOD. 2014, 124(21):

View this publication in the PUBMED database

Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes

Pleyer, L, Burgstaller, S, Stauder, R, Girschikofsky, M, Linkesch, W, Pfeilstocker, M, Autzinger, EM, Tinchon, C, Sliwa, T, Lang, A, Sperr, WR, Geissler, D, Krippl, P, Voskova, D, Rossmann, DH, Schlick, K, Thaler, J, Halter, B, Machherndl-Spandl, S, Theiler, G, Valent, P, Eckmullner, O, Greil, R
BLOOD. 2014, 124(21):

View this publication in the PUBMED database

Azacitidine in Patients with Treatment-Related Acute Myeloid Leukemia: Retrospective Analysis of the Austrian Azacitidine Registry

Pleyer, L, Burgstaller, S, Stauder, R, Girschikofsky, M, Linkesch, W, Pfeilstoker, M, Autzinger, EM, Tinchon, C, Sliwa, T, Lang, A, Sperr, WR, Geissler, D, Krippl, P, Voskova, D, Rossmann, DH, Schlick, K, Thaler, J, Halter, B, Machherndl-Spandl, S, Theiler, G, Valent, P, Eckmullner, O, Greil, R
BLOOD. 2014, 124(21):

View this publication in the PUBMED database

2013

Azacitidine in patients with WHO-defined AML – results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group.

Pleyer, L, Stauder, R, Burgstaller, S, Schreder, M, Tinchon, C, Pfeilstocker, M, Steinkirchner, S, Melchardt, T, Mitrovic, M, Girschikofsky, M, Lang, A, Krippl, P, Sliwa, T, Egle, A, Linkesch, W, Voskova, D, Angermann, H, Greil, R,
J HEMATOL ONCOL. 2013, 6: 32

View this publication in the PUBMED database

Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemia.

Valentiny, C, Mitrovic, M, Pleyer, L, Steurer, M, Willenbacher, W, Stauder, R
WIEN KLIN WOCHENSCHR. 2013, 125(1-2): 50-53.

View this publication in the PUBMED database

Complications of 5-azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome.

Melchardt, T, Weiss, L, Pleyer, L, Steinkirchner, S, Auberger, J, Hopfinger, G, Greil, R, Egle, A,
Oncol Lett. 2013, 6(6): 1756-1758.

View this publication in the PUBMED database

Lenalidomide/Rituximab Maintenance After Induction With Fludarabine/Rituximab In Combination With Escalating Doses Of Lenalidomide In Previously Untreated Chronic Lymphocytic Leukemia (CLL): The Revlirit CLL5 AGMT Phase I/II Study, Final Results

Egle, A, Steurer, M, Gassner, FJ, Geisberger, R, Melchardt, T, Pleyer, L, Weiss, L, Fridrik, MA, Thaler, J, Lang, A, Greil, R,
Blood (ASH Annual Meeting Abstracts). 2013. #4164:

View this publication in the PUBMED database

2012

Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.

Valent, P, Gastl, G, Geissler, K, Greil, R, Hantschel, O, Lang, A, Linkesch, W, Lion, T, Petzer, AL, Pittermann, E, Pleyer, L, Thaler, J, Wolf, D,
Crit Rev Oncol Hematol. 2012, 82(3): 370-377.

View this publication in the PUBMED database

Complications of 5-azacytidine: Three cases of severe colitis in a single center cohort

Melchardt, T, Weiss, L, Pleyer, L, Steinkirchner, S, Greil, R, Egle, A
ONKOLOGIE. 2012, 35: 149-149.

View this publication in the PUBMED database

2011

Complete remission of Waldenström macroglobulinemia with azacitidine and rituximab.

Weiss, L, Melchardt, T, Neureiter, D, Kemmerling, R, Moshir, S, Pleyer, L, Greil, R, Egle, A,
J CLIN ONCOL. 2011, 29(24): e696-e698.

View this publication in the PUBMED database

Activity of Azacitidine in 26 Unselected, Consecutive CMML Patients Included in the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group

Pleyer, L, Stauder, R, Burgstaller, S, Schreder, M, Tinchon, C, Pfeilstocker, M, Steinkirchner, S, Melchardt, T, Mitrovic, M, Girschikofsky, M, Lang, A, Krippl, P, Egle, A, Sliwa, T, Linkesch, W, Fridrik, MA, Greil, R
BLOOD. 2011, 118(21): 747-747.

View this publication in the PUBMED database

2010

The impact of storage effects in biobanks on biomarker discovery in systems biology studies

Balasubramanian, R, Muller, L, Kugler, K, Hackl, W, Pleyer, L, Dehmer, M, Graber, A
BIOMARKERS. 2010, 15(8): 677-683.

View this publication in the PUBMED database

Chronic Myeloid Neoplasias and Clonal Overlap Syndromes.

Greil, R, Pleyer, L, Neureiter, D, Faber, V. (editor(s)). 2010.

View this publication in the PUBMED database

Clonal Bone Marrow Failure Overlap Syndromes.

Pleyer, L, Neureiter, D, Faber, V, Greil, R,
In: Greil, R, Pleyer, L, Neureiter, D, Faber, V (Ed.) editors(s). Chronic Myeloid Neoplasias and Clonal Overlap Syndromes.. p. 281-288.

View this publication in the PUBMED database

Introduction to „Classic’ Chronic Myeloproliferative Disoderes (CMPDs)- Molecular and Cellular Biology.

Pleyer, L, Greil, R,
In: Greil, R, Pleyer, L, Neureiter, D, Faber, V (Ed.) editors(s). Chronic Myeloid Neoplasias and Clonal Overlap Syndromes.. p. 1-13.

View this publication in the PUBMED database

Essential Thrombocythemia (ET).

“Pleyer, L, Faber, V, Neureiter, D, Greil, R,

View this publication in the PUBMED database

View this publication in the PUBMED database

Rare Clonal Myeloid Diseases

Melchardt, T, Weiss, L, Pleyer, L, Neureiter, D, Faber, V, Greil, R,
“In: Greil, R, Pleyer, L, Faber, V, Neureiter, D (Eds.)

View this publication in the PUBMED database

View this publication in the PUBMED database

Primary Myelofibrosis (PMF) [Previously Chronic Idiopathic Mylofibrosis (CIMF), Myelofibrosis with Myeloid Metaplasia (MMM), Agnogenic Myeloid Metaplasia (AMM)].

Pleyer, L, Faber, V, Neureiter, D, Greil, R,
In: Greil, R, Pleyer, L, Neureiter, D, Faber, V (Ed.) editors(s). Chronic Myeloid Neoplasias and Clonal Overlap Syndromes.. p. 81-116.

View this publication in the PUBMED database

“De novo ‘Classic’ Paroxysmal Nocturnal Hemoglobinuria (PNH) (Marchiafava-Micheli Syndrome).

View this publication in the PUBMED database

View this publication in the PUBMED database

Bewegung und Krebs.

Pleyer, L, Kappacher, A, Rosenlechner, S, Greil, R,
In: Braumann, KM, Stiller, N (Ed.) editors(s). Bewegungstherapie bei internistischen Erkrankungen.. p. 223-240.

View this publication in the PUBMED database

Chronic Myelomonocytic Leukemia (CMML).

Pleyer, L, Neureiter, D, Faber, V, Greil, R,
“In: Greil, R, Pleyer, L, Neureiter, D, Faber, V (Ed.)

View this publication in the PUBMED database

View this publication in the PUBMED database

Myelodysplastic Syndromes (MDS).

Pleyer, L, Neureiter, D, Faber, V, Greil, R,
In: Greil, R, Pleyer, L, Neureiter, D, Faber, V (Ed.) editors(s). Chronic Myeloid Neoplasias and Clonal Overlap Syndromes.. p. 153-222.

View this publication in the PUBMED database

Polycythemia Vera (PV).

Pleyer, L, Neureiter, D, Greil, R,
In: Greil, R, Pleyer, L, Neureiter, D, Faber, V (Ed.) editors(s). Chronic Myeloid Neoplasias and Clonal Overlap Syndromes.. p. 51-80.

View this publication in the PUBMED database

Chronic Myeloid Leukemia (CML).

Bubnoff, N, Pleyer, L, Neureiter, D, Faber, V, Duyster, J,
In: Greil, R, Pleyer, L, Neureiter, D, Faber, V (Ed.) editors(s). Chronic Myeloid Neoplasias and Clonal Overlap Syndromes.. p. 117-152.

View this publication in the PUBMED database

HETEROGENEOUS EXPRESSION PATTERN OF HEDGEHOG SIGNALLING PATHWAY IN HEMATOPOIESIS OF MYELODYSPLASTIC SYNDROME

Neureiter, D, Kemmerling, R, Alinger, B, Kiesslich, T, Faber, V, Stocher, M, Pleyer, L, Greil, R, Dietz, O
HAEMATOL-HEMATOL J. 2010, 95: 375-375.

View this publication in the PUBMED database

2009

Vincristine, idarubicin, dexamethasone and thalidomide in scleromyxoedema.

Laimer, M, Namberger, K, Massone, C, Koller, J, Emberger, M, Pleyer, L, Hintner, H, Greil, R,
Acta Derm Venereol. 2009, 89(6): 631-635.

View this publication in the PUBMED database

Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.

Hartmann, TN, Pleyer, L, Desch, P, Egle, A, Greil, R,
Discov Med. 2009, 8(42): 157-164.

View this publication in the PUBMED database

Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Pleyer, L, Egle, A, Hartmann, TN, Greil, R,
NAT REV CLIN ONCOL. 2009, 6(7): 405-418.

View this publication in the PUBMED database

FINAL RESULTS OF ORAL FLUDARABINE WITH CONCOMITANT SUBCUTANEOUS ALEMTUZUMAB IN RELAPSED/REFRACTORY B-CHRONIC LYMPHOCYTIC LEUKAEMIA (B-CLL): THE FLUSALEM STUDY

Egle, A, Melchardt, T, Pleyer, L, Tinhofer, I, Lang, A, Keil, F, Thaler, J, Gunsilius, E, Fridrik, M, Greil, R
HAEMATOL-HEMATOL J. 2009, 94: 140-140.

View this publication in the PUBMED database

2008

Tumour-immune cell interactions modulated by chemokines.

Jöhrer, K, Pleyer, L, Olivier, A, Maizner, E, Zelle-Rieser, C, Greil, R,
EXPERT OPIN BIOL TH. 2008, 8(3): 26-90.

View this publication in the PUBMED database

Minimal Residual Disease (MRD) and T/NK Cell Dynamics during Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): Riskfactor Stratification in the Chairos Study.

Egle, A, Weiss, L, Gassner, F, Russ, G, Pleyer, L, Gunsilius, E, Tinhofer, I, Thaler, J, Petzer, AL, Greil, R
BLOOD. 2008, 112(11): 1089-1089.

View this publication in the PUBMED database

2007

Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C.

Pleyer, L, Went, P, Russ, G, Prinz, E, Faber, V, Röwert, HJ, Karlbauer, R, Greil, R,
WIEN KLIN WOCHENSCHR. 2007, 119(7-8): 254-258.

View this publication in the PUBMED database

Regulation of apoptosis.

Pleyer, L, Tinhofer, I, Greil, R,
In: Hakan Mellstedt DSDBRG (Ed.) editors(s). ESMO Handbook of principles of translational Research.. p. 67-69.

View this publication in the PUBMED database

Entwicklungen und Perspektiven in der Behandlung der Lymphatischen Neoplasien.

Pleyer, L, Desch, P, Greil, R,
In: Greil, R (Ed.) editors(s). Lymphoproliferative Erkrankungen.. p. 139-155.

View this publication in the PUBMED database

Planned first efficacy and safety analysis of de-intensified induction with fludarabine, cyclophosphamide plus rituximab (FCR) followed by fludarabine plus rituximab (FR) and remission maintenance therapy with rituximab in previously untreated B-chronic lymphocytic leukemia (B-CLL): The chairos study

Egle, A, Weiss, L, Russ, G, Thoedtmann, R, Pleyer, L, Gastl, G, Thaler, J, Petzer, A, Tinhofer, I, Greil, R
BLOOD. 2007, 110(11): 609A-609A.

View this publication in the PUBMED database

2004

Attenuation of virulence properties of Candida albicans in vitro by basidiomycete metabolites

Pleyer, L, Ressler, S, Berg, A, Wurzner, R, Dierich, MP
INT J MED MICROBIOL. 2004, 294: 192-192.

View this publication in the PUBMED database

Our aim is to better understand how we can use targeted immune therapies to help the body to eliminate myeloid cancer cells

Team

Priv.Doz. OÄ Dr.DI Lisa Pleyer

OA. Dr. Konstantin Schlick

Dr. Felicia Vlad Rusen

OA Dr. Konstantin Schlick

Dr. Petra Altenhofer
(Biologist)

M.Sc. Barbara Seitler

M.Sc. Kathrin Bracher

M.Sc. Johannes Bischof

B.Sc. Thomas Hanner

Former Staff:

und/oder in Karenz befindliche Mitarbeiter/innen

M.Sc. Katrin Wörndl, Biologin
M.Sc. Ulrike Seidl, BMA (Masterarbeit)
M.Sc. Roman Gangl

M.Sc. Erika Nußbaumer

M.Sc. Johannes Bischof

Co-operation partner:

Priv.Doz. Dr. Tanja Hartmann, Biologin
Dr. Elisabeth Bayer, Biologin
Dr. Clemens Hufnagl, BMA
Dr. Franz Gassner, Biologe

Do you have a request or any questions?

Feel free to contact us – we will get back back to you as soon as possible.